Olga Rivero-Menendez1, Manuel Cuenca-Estrella1, Ana Alastruey-Izquierdo1. 1. Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain; Spanish Network for the Research in Infectious Diseases (RD16/CIII/0004/0003), Instituto de Salud Carlos III, Madrid, Spain.
Abstract
BACKGROUND: APX001A (E1210) is a novel broad-spectrum antifungal agent that inhibits Gwt1p, a protein that plays an important role in fungal cell wall integrity. Previous studies have shown that APX001A has broad activity against most species of Candida, Aspergillus, Scedosporium, Fusarium and Mucorales. OBJECTIVES: To investigate the in vitro activity of APX001A against 200 isolates belonging to 20 different species of Fusarium, Scedosporium, Lomentospora, Alternaria, cryptic species of Aspergillus and Mucorales. METHODS: APX001A and comparators were tested using EUCAST and CLSI methodologies for broth microdilution susceptibility testing of antifungal agents. RESULTS: APX001A was generally inactive against Mucorales, but active against all cryptic species of Aspergillus and Scedosporium/Lomentospora species. CONCLUSIONS: APX001A shows encouraging in vitro activity against some emerging fungi that are hard to treat with currently available antifungals.
BACKGROUND: APX001A (E1210) is a novel broad-spectrum antifungal agent that inhibits Gwt1p, a protein that plays an important role in fungal cell wall integrity. Previous studies have shown that APX001A has broad activity against most species of Candida, Aspergillus, Scedosporium, Fusarium and Mucorales. OBJECTIVES: To investigate the in vitro activity of APX001A against 200 isolates belonging to 20 different species of Fusarium, Scedosporium, Lomentospora, Alternaria, cryptic species of Aspergillus and Mucorales. METHODS: APX001A and comparators were tested using EUCAST and CLSI methodologies for broth microdilution susceptibility testing of antifungal agents. RESULTS: APX001A was generally inactive against Mucorales, but active against all cryptic species of Aspergillus and Scedosporium/Lomentospora species. CONCLUSIONS: APX001A shows encouraging in vitro activity against some emerging fungi that are hard to treat with currently available antifungals.
Authors: Martin Hoenigl; Rosanne Sprute; Matthias Egger; Amir Arastehfar; Oliver A Cornely; Robert Krause; Cornelia Lass-Flörl; Juergen Prattes; Andrej Spec; George R Thompson; Nathan Wiederhold; Jeffrey D Jenks Journal: Drugs Date: 2021-10-09 Impact factor: 9.546
Authors: Teclegiorgis Gebremariam; Sondus Alkhazraji; Abdullah Alqarihi; Nathan P Wiederhold; Karen Joy Shaw; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim Journal: Antimicrob Agents Chemother Date: 2020-05-21 Impact factor: 5.191